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Background: The RASCAL (Refractory Angina Spinal Cord stimulation and usuAL care) pilot study seeks to assess
the feasibility of a definitive trial to assess if addition of spinal cord stimulation (SCS) to usual care is clinically
superior and more cost-effective than usual care alone in patients with refractory angina.
Methods/design: This is an external pilot, patient-randomized controlled trial.
The study will take place at three centers in the United Kingdom - South Tees Hospitals NHS Foundation Trust (The
James Cook University Hospital), Dudley Group of Hospitals NHS Foundation Trust, and Basildon and Thurrock
University Hospitals NHS Foundation Trust.
The subjects will be 45 adults with refractory angina, that is, limiting angina despite optimal anti-angina therapy,
Canadian Cardiovascular Society Functional Classification Class III and IV, angiographically documented coronary
artery disease not suitable for revascularization, satisfactory multidisciplinary assessment and demonstrable ischemia
on functional testing.
The study will be stratified by center, age and Canadian Cardiovascular Society Functional Classification.
Interventions will involve spinal cord stimulation plus usual care (‘SCS group’) or usual care alone (‘UC group’). Usual
care received by both groups will include consideration of an education session with a pain consultant, trial of a
transcutaneous electrical neurostimulation, serial thoracic sympathectomy and oral/systemic analgesics.
Expected outcomes will be recruitment and retention rates; reasons for agreeing/declining participation; variability
in primary and secondary outcomes (to inform power calculations for a definitive trial); and completion rates of
outcome measures. Trial patient-related outcomes include disease-specific and generic health-related quality of life,
angina exercise capacity, intake of angina medications, frequency of angina attacks, complications and adverse
events, and satisfaction.
Discussion: The RASCAL pilot trial seeks to determine the feasibility and design of a definitive randomized
controlled trial comparing the addition of spinal cord stimulation to usual care versus usual care alone for patients
with refractory angina.
Fifteen patients have been recruited since recruitment opened in October 2011. The trial was originally scheduled
to end in April 2013 but due to slow recruitment may have to be extended to late 2013.
Trial registration: ISRCTN65254102
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Refractory angina (RA) is defined by a European Society of
Cardiology taskforce as a “clinical diagnosis based on the
presence of symptoms of stable angina, thought to be
caused by ischemia due to advanced coronary disease and
which are not controllable by a combination of maximal
medical therapy, bypass surgery and percutaneous interven-
tion” [1]. Others have proposed that RA is an indication in
which patients are refractory to drug therapy but also un-
suitable for revascularization. The United Kingdom (UK)
national chronic RA guideline group defines RA as
“chronic stable angina that persists despite optimal medica-
tion and when revascularization is unfeasible or where the
risks are unjustified” [2]. The most frequent reasons that
patients are unsuitable for revascularization include un-
favorable coronary anatomy, multiple previous revas-
cularization procedures (both percutaneous and surgical),
the lack of suitable bypass graft targets or conduits, and sig-
nificant extra-cardiac co-morbidities [3]. It is estimated that
in Europe the incidence of RA is 100,000 new cases per
year [4]. RA patients experience severe chest pain, which
can result in multiple hospitalizations and low levels of
health-related quality of life [3]. A number of therapies have
been recommended for the treatment of RA following
optimization of their cardiovascular drug therapy, that is,
beta blockers, nitrates, potassium agonists and newer
generation drugs (for example, ranolazine) [1,3]. These
additional therapies include sympathectomy, analgesics
(usually opiate-based), angina management programs, sti-
mulation induced analgesia, stellate ganglion block, epi-
dural blocks, spinal cord stimulation (SCS), enhanced exter-
nal counterpulsation and percutaneous laser myocardial
revascularization [4,5].
The use of spinal cord stimulation (SCS) for angina was
first described in 1987. SCS is a reversible procedure in
which electrodes are implanted in the epidural space to
stimulate the dorsal columns of the spinal cord [6]. The
technique has been described in detail elsewhere [7]. SCS
has been successfully used to relieve pain in a number of
chronic conditions, including neuropathic pain and pain
due to peripheral vascular disease [8].
The mechanism of action of SCS in neuropathic pain is
well documented. For ischemic pain there are a number of
proposed mechanisms. It is believed to have its effects by a
combination of modulation of pain pathways within the
central nervous system and anti-ischemic mechanisms.
SCS modulates the autonomic nervous system, suppresses
intrinsic cardiac nerve activity independent of beta
sympathetic nervous system activity and is cardio-
protective [9,10].
Systematic review and meta-analysis
To summarize the current evidence for the use of SCS
for RA, we updated a recent systematic review [11]. Wesearched a number of electronic databases including
Medline, Embase and Cochrane Library up to April
2011 (with a further search in October 2012) to identify
randomized controlled trials (RCTs) of SCS in RA. The
reference lists of included studies were checked for po-
tential additional studies. The search strategy, inclusion
and exclusion criteria, study selection, data extraction
and risk of bias assessment are detailed elsewhere [11].
We identified eight RCTs that included a total of 322
RA patients (see Additional file 1: Table S1) [12-19]. Five
studies compared SCS stimulation (‘SCS ON’) to ei-
ther sub-threshold or no SCS stimulation (‘SCS OFF’)
[13,16-19], one study compared SCS to usual care [14],
and two studies compared SCS with an alternative ther-
apy (that is, coronary artery bypass graft [12] and percu-
taneous myocardial laser vascularization [13]). The risk
of bias of five trials was judged to be high (that is, met
two out of five criteria) and three trials to be low to
moderate (that is, met three or more out of five criteria)
(see Additional file 1: Table S2).
Findings are presented according to the two broad cat-
egories of control group, that is, SCS versus active inter-
vention and active SCS versus no or sub-threshold SCS.
The between group differences of active SCS (‘SCS ON’)
versus no or inactive SCS (‘SCS OFF’) trials were quanti-
tatively pooled using a conservative Der Simonian ran-
dom effects meta-analysis model to take account of the
potential heterogeneity (both clinical and methodo-
logical) across trials [20]. Given the variety of exercise
capacity, consumption of nitrate medication and health-
related quality of life outcomes were reported, results
were expressed as a standardized mean difference
(SMD). SMD is a summary statistic used when trials as-
sess the same outcome, but measure it in a variety of
ways [21]. The SMD expresses the size of the treatment
effect in each trial relative to the study variance or
standard deviation observed in the trial. All analyses
were performed using RevMan, version 5.0 (www.cc-ims.
net/RevMan).
Meta-analysis results are shown in Additional file 1:
Figure S1. Outcomes of SCS were similar when directly
compared to either coronary artery bypass grafting or
percutaneous myocardial laser revascularization. Compared
to a ‘no stimulation’ control, there was some evidence of
improvement in all outcomes following SCS implantation
with gains observed in pooled exercise capacity (SMD: 0.62,
0.03 to 1.21, Additional file 1: Figure S1a), short acting
nitrate consumption (SMD: -0.65, 95%, -1.34 to 0.05,
Additional file 1: Figure S1b), and health-related quality of
life (SMD: 0.61, 95% CI: 0.13 to 1.09, Additional file 1:
Figure S1c).
SCS-related complications were reported in five trials
[12-14,16,18] and included infections (1 out of 104 patients,
1%) and lead migrations or fractures (10 out of 128
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reported and in no studies was there a statistically signifi-
cant difference in events between SCS and the comparator
[12,13,19].
UK survey of current RA management
In designing a pragmatic trial of SCS for RA, it is
important to determine what would constitute usual
medical management and how this care might vary
across centers in the UK.
It is likely that the management of patients with RA
varies considerably. We were aware of only one UK spe-
cialist center for RA - the National Refractory Angina
Centre in Liverpool. Outside of this center, the manage-
ment of RA probably varies considerably by locality;
some RA patients being managed within a cardiology
unit, and others by a specialist pain team or a combin-
ation of the two. Furthermore, in the absence of
authoritative evidence-based clinical guidelines for the
management of RA, clinicians and centers may be
recommending different therapies.
To assess current UK RA management and to quantify
the potential variation in this practice, we undertook a
national survey. Contact details were obtained for all UK
pain centers (from the Dr Foster database) and cardiac
centers (from the central cardiac audit database). After a
number of rounds of drafting, we finalized a two-page
questionnaire. A questionnaire and pre-paid return en-
velope were posted to all pain and cardiac units in April
2011. A follow-up questionnaire was posted to non-
responding units in July 2011.
A total of 552 questionnaires was sent out and 215 re-
plies were received (41%). Of these, 94 (44%) were from
pain units, 49 (23%) were from cardiology units and the
remainder (34%) did not indicate their specialty. The
vast majority used either the European Society of Cardi-
ology RA definition [1] (41%) or the UK National RA
group definition [2] (54%) in their practice, the remain-
der (5%) stated that they used a different definition. Only
11 (5%) centers replied that they used a protocol or
guideline for the management of their RA patients with
RA. The drug therapies offered to patients with RA in
addition to their cardiovascular drugs varied greatly with
a total of 16 differing therapies identified. The most
common treatments included regular slow release
opiates (N = 122 units, 56%), instant release opiates as
on demand prescriptions (101, 47%), transcutanous
nerve stimulation (TENS) (116, 54%), exercise programs
(84, 39%), cognitive behavioral therapy (72, 33%) and
education (61, 28%). A total of 35 units (16%) used SCS.
The complete list of RA treatments offered by units is
summarized in Additional file 1: Figure S2.
Of the 192 (89%) centers who responded to the
statement that ‘SCS was a suitable therapy for pa-tients with RA’, 10% ‘strongly agreed’, 42% ‘agreed’,
42% were ‘unsure’, 5% ‘disagreed’ and 1% ‘strongly
disagreed’. Of those who were unsure or disagreed,
reasons given were that they did not know where to
refer patients for SCS (26%), considered the clinical
current evidence for SCS to be poor (46%), regarded
SCS as too expensive (15%), did not understand how
SCS worked (5%), were concerned that SCS may
mask serious disease or felt RA did not require anal-
gesia (1%). A total of 75 centers (44%) stated that
they would be interested in participating in a multicenter
trial involving patients with RA.
Pilot study objectives
It is hypothesized that the addition of SCS to usual care will
have superior clinical effectiveness and cost-effectiveness
compared to usual care alone in patients with RA. The
RASCAL (Refractory Angina Spinal Cord stimulation and
usuAL care) pilot study seeks to assess the feasibility of a
definitive trial to address this hypothesis. RA patients will
be randomized to SCS plus usual care (‘SCS group’) or
usual care alone (‘UC group’).
The objectives of this study are to:
i. To assess recruitment, uptake and retention of
patients in both groups.
ii. To assess the feasibility and acceptability of SCS
treatment from the point of view of patients and
referring physicians.
iii. To assess the feasibility and acceptability of
standardizing usual care from the point of view of
patients and referring physicians.
iv. To test the feasibility and acceptability of the
proposed trial outcome measures in both groups.
The results from this pilot study will inform the design
and power for a definitive multicenter RCT.
Methods/design
Design
This external pilot study is designed as a pragmatic
multi-center study where RA patients are randomized in
a 1:1 ratio to either the SCS or UC group. Given the
paresthesia associated with SCS, it is not possible to
blind patients, clinicians or researchers to group alloca-
tion. However, we will seek to blind those conducting
the exercise capacity assessment. Research nurses
conducting the data collection on the three sites will not
be involved with patient care. The study design is
summarized in Figure 1.
Study population
Adults (≥18 years) with RA from South Tees Hospitals
NHS Foundation Trust (The James Cook University
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Trust and Basildon and Thurrock University Hospitals
NHS Foundation Trust will be invited to participate in
the study.
Inclusion criteria
 limiting angina despite optimal anti-angina
therapy
 Canadian Cardiovascular Society Functional
Classification of Angina III and IV
 angiographically documented coronary artery
disease
 coronary artery disease not suitable for
revascularization in the opinion of the referring
cardiologist/cardiothoracic surgeon
 satisfactory multidisciplinary assessment in
accordance with British Pain Society guidelines
for SCS [22]
 demonstrable ischemia on functional testing
Exclusion criteria
 presence of pacemaker or implanted defibrillator
that is incompatible with SCS
 patient refusal to participate in the study
 presence of co-morbidity considered by the
assessing clinician to overshadow the effect of the
angina or render the patient an unsuitable candidate
for neuromodulation (for example, advanced spinal
disease or deformity)
 poor cognitive ability
 on-going anticoagulation therapy; where
anticoagulants cannot be safely discontinued without
jeopardizing patient safety
 patients who may require regular MRI scans
 pregnant or lactating females
 patients with special communication needs
Recruitment of patients
Patients will be identified in the outpatient clinics of the
cardiology departments of the three participating
hospitals. Patients identified as suffering from RA will be
discussed by the referring cardiologist with a colleague
at consultant level to confirm the diagnosis. Following
confirmation that the patient is suffering from RA they
will be referred by letter, as well as, verbally to the pain
clinic for treatment. Referred patients with a diagnosis
of RA will have their notes reviewed by the research
team to determine that they fulfill the trial inclusion cri-
teria and will be invited to attend a multidisciplinary as-
sessment in the pain clinic outpatient department.
Informed consent will be obtained from suitable
patients by one of principal investigators (SE, JR or ST)or a delegated sub-investigator at each site. Patients will
be provided with a patient information sheet and
allowed a reasonable period of time to reflect upon their
participation. A member of the research team will an-
swer all questions regarding the study and risks of SCS
before the patient signs an informed consent form.
Sample size
A power calculation was not performed for this study to
detect a clinically or economically meaningful difference
in outcomes. Rather, the sample size was chosen to in-
form the feasibility objectives of this study, that is, pro-
vide estimates of the likely rates of recruitment and
retention, and to yield estimates of the variability of the
primary and secondary outcomes to inform power
calculations for a subsequent full-scale RCT. We seek to
randomize a total of 45 RA patients (that is, 15 patients/
center).
Randomization
Patients will be randomized sequentially, as they be-
come eligible for randomization. The sequence of ran-
domization will be computer-generated and stratified by
hospital, age and Canadian Cardiovascular Society func-
tional angina level. To ensure concealment, at the end of
the screening visit the research nurse at each center will
email the trial statistician (RST) with the relevant patient
details, who will then allocate the patient. An email




For those patients allocated to receive SCS, the interven-
tion will be started within six weeks from the date of
randomization with an acute on-table trial of SCS
followed by a final stage implant if the trial is successful.
SCS will be implanted by an experienced clinician
(that is, one who has performed ≥15 SCS implants in
the prior 12 months). The procedure will consist of
inserting one or two epidural leads through a needle into
a thoracic epidural interspace under local anesthetic
with patients either in a prone lateral or sitting position
according to patient and operator preference. Once in
position, the leads will be connected to an external
stimulator and the position adjusted to obtain optimum
coverage of the painful area. In cases where the pares-
thesias cover 80% or more of the painful area the leads
will be anchored to the spine via a small incision and
connected via tunneled subcutaneous extensions, where
required, to an implanted pulse generator placed in the
anterior abdominal wall or the buttock according to
patient’s and operator preference.
Excluded (N= )
Found not to be suitable 
N=
Refused participation N=
Allocated to SCS group N=
Received SCS implant N=
Allocated to CMM group N=
Received CMM N=





N= (%) Excluded (N= )
Did not reply N=



























Figure 1 CONSORT flow for pilot trial.
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age of the painful area, or if painful sensations are
generated when the temporary stimulator is switched
on, the procedure will be aborted, the leads removed
and no pulse generator implanted (‘failed trial’).
Patients who have a failed trial of SCS will continue
to receive treatment and follow-up as per the study
protocol.
Patients implanted with an SCS will be instructed how
to adjust their device to generate comfort level paresthe-
sias. They will be instructed to do this regularly for two
hours three times daily, to terminate any angina attack
for as long as is necessary, and before any exertion
known or anticipated to generate angina pain. We will
document usage of the SCS device through telemetry
interrogation at the three- and six-month visits. The
SCS devices to be used within this study are CE
(Conformité Européene) marked and used within
their intended license.Usual care
Both groups of patients will receive the following com-
bination of therapies started, if possible, on the day of
randomization:
– education session with a pain consultant
– trial of a transcutaneous electrical nerve stimulation
(TENS)
– serial thoracic sympathectomy
– oral/systemic analgesics and adjuvant analgesia
Patients who have already tried and failed to obtain re-
lief from any of the sequence of therapies above will be
moved on to the next therapy down the list if, in the
judgment of the site principal investigator and the pa-
tient, the trial was considered to be adequate and well
conducted. Following completion of the above sequence,
the treating physician may apply any therapy deemed ap-
propriate with the exception of repeat coronary artery
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or percutaneous myocardial laser revascularization or
enhanced external counterpulsation. We will document
all UC care component treatments received by both
groups of patients with start and end date where
appropriate.
Pilot study endpoints
The pilot study will collect and report on the following
outcomes:
1. Recruitment and retention: we will document
procedures for recruiting patients in both groups and
any problems that arise during this process.
Retention will be assessed by documenting the
number of drop outs and lost to follow up in both
groups.
2. Feasibility and acceptability of design: we will assess
the time for attainment of patient number targets in
each center, the proportion of suitable patients who
fail to provide consent and the ratio of patients
screened vs. randomized.
3. Feasibility and acceptability of treatment: patients
will be asked to assess their willingness to
recommend SCS or UC to other patients.
4. Feasibility and acceptability of proposed patient
outcome measures: number of returned and
complete outcome assessments assessed.
5. Outcome variance: mean and standard deviation for
all outcomes will be calculated for each group at all
assessment visits (to inform power calculations for a
definitive trial).
Trial outcome measures
Patient outcomes will be collected at clinic visits at base-
line (pre-randomization), and three and six months
post-randomization unless otherwise stated.
Primary outcome
Disease specific health-related quality of life will be
assessed using the disease specific Seattle Angina Ques-
tionnaire (UK version) [23].
Secondary outcomes
– Intake of angina medications and frequency of
angina attacks: We will supply patients with an
angina diary to record the frequency of their angina
attacks as well as the use of anti-angina medication.
The average number of angina attacks per week will
be recorded at baseline. Patients will be asked to fill
the diary for one week prior to the three- and six-
month visits. All patients will receive a phone call
reminder from the research team asking them tostart the diary. Any changes to cardiac medication
will be noted during follow-up visits.
– Exercise capacity (at baseline and six months only)
will be assessed by a symptom-limited treadmill
(modified Bruce protocol). For each patient the
same test will be undertaken at baseline and six
months.
– Complications and adverse events: The nature and
frequency of device-specific and non-device events
by direct questioning of the patient and, where
necessary, review of medical notes.
– Healthcare utilization (for example, cardiac specific
hospitalizations and primary care visits,
management of complications/adverse events) will
be assessed at six months using the patient report. If
necessary, the patient’s General Practitioner will be
contacted by letter to seek these details. We will
collect information on all current medication dosing
and frequency at baseline and at the three- and six-
month follow-ups.
– Generic health-related quality of life: Assessed using
the EuroQol (EQ-5D) and Short Form-36 (SF-36)
questionnaires [24,25].
– Satisfaction: At the six-month follow-up visit,
patients will be asked to answer the following
questions:
o Are you satisfied with the pain relief provided by
your treatment?
(Very Satisfied/Satisfied/Unsatisfied/Very Unsatisfied)
o Based on your experience so far, would you have
agreed to this treatment?
(Definitely Yes/Yes/No/Definitely No)
o Can you tell us how acceptable these treatments
were to you? (a list of treatments will be provided)
(Extremely acceptable/Acceptable/Not acceptable/Ex-
tremely unacceptable /Not Applicable)Statistical analysis
Given the pilot nature of this trial, we do not propose to
formally, statistically test differences in outcomes and
costs between or within groups. Instead, for all groups
we will estimate SCS and UC group mean and standard
deviation (or frequency) for all outcomes at each assess-
ment point. All analyses will be conducted using STATA
v.11 (Stata Corporation, College Station, Texas, USA).
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South Tees Hospitals NHS Foundation Trust will act as
the lead sponsor for the trial. All research team
members obtaining informed consent will have appro-
priate training and current Good Clinical Practice (GCP)
certification. In line with the International Conference
on Harmonization (ICH)/GCP, patients will be given a
copy of their consent form to keep for reference; a fur-
ther copy of the consent form will be filed in the
patient’s health records. The original version will be filed
in the Investigator Site File on site. A unique study label
will be fixed to the front of the patient’s health records
to indicate their participation in the study. We will con-
tact the patient’s general practitioner by letter to inform
them of the patient’s participation in the study.
The trial office will receive completed case report
forms from the two other centrrs via the postal service
as well as the site database. Upon receipt, data forms will
be checked for completeness and merged into a master
chart, which will be communicated to the study
statistician. Patient confidentiality will be maintained at
every stage and we will comply with the Data Protection
Act (1998).
Patients may withdraw from the trial or the trial treat-
ment at any time without prejudice. If a patient
withdraws from the trial treatment, then they will be
followed up wherever possible and data collected as per
protocol until the end of the trial. The only exception to
this is where the patient also explicitly withdraws con-
sent for follow-up. Patients may be withdrawn from the
study at the discretion of the Investigator/Trial Steering
Committee due to safety reasons. South Tees Hospitals
NHS Foundation Trust should be notified by faxing a
notification of the patient withdrawal form within 48
hours of withdrawal. All adverse events and serious ad-
verse events will be recorded at each visit and in be-
tween visits by the research nurses at each site on an
adverse event log. The study coordinator will liaise with
the study statistician on a regular basis and the Chief In-
vestigator will be made aware of all adverse events and
serious adverse events as they happen. In the event that
the patient is withdrawn due to safety reasons, a serious
adverse event or suspected unexpected serious adverse
reaction notification should also be sent to the South
Tees Hospitals NHS Foundation Trust Research and De-
velopment Department.Trial steering committee
The trial will be overseen by the Trial Steering Commit-
tee (TSC). The TSC will consist of the chief investigator
(SE), study coordinator (MB), site investigators (JR, ST,
MdB), trial statistician (RST) and the following inde-
pendent members:Dr Duncan McNab (Chair) - Consultant cardiologist,
Papworth Hospital NHS Foundation Trust and Mr
David Richardson (lay member) - British Pain Society
Patient Liaison Committee.
TSC meetings will be held not less than once a year.
Routine business will be conducted by email, post or
teleconferencing. In discussion with the TSC, it was
agreed that a separate Data Monitoring Committee will
not be necessary in this study. Instead, the independent
TSC members will be presented with the safety data
prior to meetings.Trial management group
The trial administration will be overseen by a trial man-
agement group (TMG) chaired by the Chief Investigator
(SE). Membership of the TMG includes: the principal in-
vestigator on all three trials sites (SE, JR, ST), study
statistician (RST), study coordinator (MB) and study
nurses (MB, RA and SM). The TMG will meet at six
monthly intervals either face to face or by tele/video
conferencing. The trial will be coordinated by the study
coordinator (MB) based at The James Cook University
Hospital. All day-to-day non-clinical coordination of the
trial will be the responsibility of the trial coordinator. All
clinical coordination of the trial will be the responsibility
of the Chief Investigator. The Chief Investigator will as-
sume responsibility for the overall management and con-
duct of the trial. Each principal investigator will assume
responsibility for leading the trial in their center. The
trial office team will distribute the clinical research
forms to participating centers, monitor the collection of
data, process data, seek missing data and clarify ambigu-
ous data, ensure the confidentiality and security of all
trial forms and data, and organize TSC meetings.Discussion
Our updated systematic review and meta-analysis shows
that SCS appears to be an efficacious and safe treatment
option in the management of RA. Nevertheless, that evi-
dence is based on small trials of variable quality; our
review supports the current American College of Cardi-
ology/American Heart Association Grade ‘IIb evidence’
classification (that is, “conflicting evidence and/or diver-
gence of opinion about the usefulness/efficacy of a pro-
cedure or treatment”) for SCS in RA patients [26].
Furthermore, the National Institute for Health and Clin-
ical Excellence (NICE) has recently called for further
high quality RCT evidence in order to confirm the clin-
ical and cost-effectiveness evidence before SCS can be
accepted as a routine treatment for RA in the UK [27].
That our national survey shows the variability in how
UK centers currently manage their RA patients is chal-
lenging to the design of a pragmatic trial of SCS.
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feasibility of undertaking a definitive pragmatic RCT
comparing the clinical and cost-effectiveness of the
addition SCS to UC versus UC alone in RA patients.
While we have attempted to standardize usual care, we
will also record the variation (both within and between
centers) in the usual care received by patients in this
study. The results of this pilot will inform the design of
a definitive RCT.
Trial status
The RASCAL pilot trial began recruitment in October
2011. Fifteen patients have been recruited to date
(1st December 2012). The trial was originally scheduled
to end in April 2013. However, due to slow recruitment,
trial end may have to be extended to late 2013.
Additional file
Additional file 1: Table S1. Systematic review – Characteristics of
included trials. Table S2. Systematic review – Risk of bias of included
trials. Figure S1a. Systematic review – Between group comparison in
exercise-capacity. Figure S1b. Systematic review – Between group
comparison in nitrate drug consumption. Figure S1c. Systematic review
– Between group comparison in health-related quality of life. Figure S2.
National survey – Frequency of RA therapy use across UK centers.
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